Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 448

Results For "LA"

8545 News Found

Merck receives EC approval for Winrevair for treatment of PAH
Drug Approval | August 27, 2024

Merck receives EC approval for Winrevair for treatment of PAH

Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe


Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
News | August 27, 2024

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration


Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
Clinical Trials | August 26, 2024

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India


Akums appoints Amrut Medhekar as CEO - CDMO Business
People | August 26, 2024

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience


Akums Q1 FY25 revenue up 5.1%
News | August 26, 2024

Akums Q1 FY25 revenue up 5.1%

The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually


BioIVT acquires ZenBio
News | August 25, 2024

BioIVT acquires ZenBio

ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise


BI Sky Global successfully completes FDA MoCRA registration
Drug Approval | August 25, 2024

BI Sky Global successfully completes FDA MoCRA registration

MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States


Zydus to acquire 50% stake in Sterling Biotech from Perfect Day
News | August 24, 2024

Zydus to acquire 50% stake in Sterling Biotech from Perfect Day

The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets


Wanbury receives EIR from FDA for Patalganga facility
Drug Approval | August 23, 2024

Wanbury receives EIR from FDA for Patalganga facility

USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation